Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMTXWCZ)

• Drug Name: LFM-A13 Drug Info
• Synonyms: lfm-a13; 244240-24-2; (Z)-2-cyano-N-(2,5-dibromophenyl)-3-hydroxybut-2-enamide; SMR001230714; SR-01000075965; 62004-35-7; C11H8Br2N2O2; 2-Cyano-N-(2,5-dibromophenyl)-3-hydroxy-2-butenamide; BiomolKI_000050; LFMA13; BiomolKI2_000056; AC1L1H0E; AC1NS4I5; Lopac0_000650; SCHEMBL51142; BSPBio_001239; BMK1-F2; MLS006010694; MLS002153290; GTPL9262; CHEBI:95065; 2-cyano-N-(2,5-dibromophenyl); MolPort-003-958-579; HMS1362M21; HMS3403M21; HMS2235P16; HMS1990M21; HMS1792M21; BCP12817; 3781AH; s7734; BS0111; ZINC37868487; AKOS024456516; CS-3890

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 54676905
  ChEBI ID: CHEBI:95065
  TTD Drug ID: DMTXWCZ

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tyrosine-protein kinase BTK (ATK)	TTGM6VW	BTK_HUMAN	Inhibitor	[1]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Tyrosine-protein kinase BTK (ATK)	DTT	BTK	3.838	3.897	5.053	5.897

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

• The Studied Disease: Discovery agent
• ICD Disease Classification: N.A.

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Tyrosine-protein kinase BTK (ATK)	DTT	BTK	3.54E-01	0.24	0.56

References

• [1] A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.